May 09, 2014
A Georgia federal judge refused Friday to allow Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. to appeal a court's refusal to dismiss the Federal Trade Commission's pay-for-delay antitrust claims under the Noerr-Pennington doctrine, even though a federal court approved the underlying AndroGel patent settlement.
April 23, 2014
Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. on Tuesday moved to immediately appeal a ruling that they were not immune from the Federal Trade Commission's pay-for-delay antitrust claims under the Noerr-Pennington doctrine, even though a federal court signed off on the underlying patent settlement.
April 21, 2014
A Georgia federal judge on Monday rejected a renewed bid by Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. to nix the Federal Trade Commission's pay-for-delay case against them, finding that their patent settlement over testosterone replacement treatment Androgel is not entitled to Noerr-Pennington antitrust immunity.
March 04, 2014
Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. urged a Georgia federal judge on Monday to nix the Federal Trade Commission's pay-for-delay case against them, saying their patent settlement was protected under Noerr-Pennington antitrust immunity.
January 17, 2014
Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. once again moved to dismiss the Federal Trade Commission's pay-for-delay case against them Wednesday, arguing they were protected from the government's antitrust claims because a federal court had approved the underlying patent settlement.
December 12, 2013
The Federal Trade Commission's pay-for-delay case against Actavis Inc. and other drugmakers is now set to resume nearly six months after the U.S. Supreme Court revived the suit, with a Georgia judge on Tuesday giving the defendants 21 days to respond to the watchdog's complaint.
April 09, 2009
A judge has transferred the Federal Trade Commission's ongoing battle against reverse payment settlements out of a California federal court — a significant loss for the agency in a heated venue dispute with a group of pharmaceutical companies in the case.